NicAlert™ employs Nymox's proprietary technology to measure levels of cotinine, a metabolite of nicotine widely accepted to determine tobacco product use and second-hand smoke exposure. The product requires no instruments for its use and provides an on-site visual read-out of the level of tobacco use or exposure within minutes.Independent studies have confirmed the accuracy and effectiveness of Nymox's testing technology. Recently published independent studies confirming the accuracy of NicAlert™ to verify smoking status as compared to much more complex and expensive laboratory testing include Nicotine Tob Res. 2013 Mar 20. [Epub ahead of print] and Drug Alcohol Depend. 2011; 119: 130–133. An earlier study by researchers at the Centers for Disease Control and Prevention (CDC) found that NicAlert™ measurements correlated well with the far more complex laboratory testing (liquid chromatography-mass spectrometry) used in the CDC laboratory (Journal of Analytical Toxicology 2005; 29: 814-818). Other studies have also found the technology employed in NicAlert™ to be accurate, rapid and cost-effective (Cancer Epidemiology, Biomarkers & Prevention 2007; 16:1858-62; Cancer Epidemiology, Biomarkers & Prevention 2002; 11:1123-1125; Nicotine & Tobacco Research 2002; 4:305-9). NicAlert™ comes in two formats: NicAlert™ Saliva which uses saliva samples for verifying smoking status and measuring high levels of consumption and NicAlert™ Urine which uses urine samples and can provide data not only on smoking status but also second-hand smoke exposure and levels of tobacco product use. More information about Nymox is available at www.nymox.com , email: firstname.lastname@example.org, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: For Further Information Contact: Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com